EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?

Ian F Tannock iD, Ajay Aggarwal, Haydee Verduzco-Aguirre, Brooke E Wilson

American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)

DOI: 10.1200/edbk-26-517738 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Ian F Tannock und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre & University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Medical Oncology, Health Services Accessibility, Neoplasms, Quality of Health Care. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Health systems, oncologists, and patients face a crisis in value of cancer care that has several components: interpretation of meaningful benefit, cost, and affordability that limits access to treatment and effective delivery of evidence-based care. Value in health care has several definitions but can be defined as benefit/cost, which can be explicitly measured using cost-effectiveness analyses and used to shape coverage decisions for health systems. In addition to drug costs, costs can also include physical costs (ie, clinical toxicities and harm), productivity losses (from inability to work because of treatment effects), and time away from family and friends. Low-value treatments include those that offer limited clinical benefit and score poorly on scales such as the European Society of Medical Oncology Magnitude of Clinical Benefit Scale and the overuse, misuse, or underuse of therapies that provide clinical benefit. Opportunity costs are what is given up when one intervention is chosen over another. Opportunity costs of low-value care translate into patient and societal harm and limit access to more effective treatments. Solutions to the value crisis require recognition of low-value care and quality improvement programs to prevent its use and support high-level care. Drug substitution and dose and schedule reduction when supported by evidence can also improve the value of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical OncologyHealth Services AccessibilityNeoplasmsQuality of Health CareHumansCost-Benefit AnalysisValue-Based Health CareCost-Effectiveness Analysis

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre & University of Toronto, Toronto, ON, Canada.
  • London School of Hygiene and Tropical Medicine, Guys and St Thomas NHS Trust, London, United Kingdom.
  • Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute & Departments of Oncology and Public Health Sciences, Queen's University, Kingston, ON, Canada.

ORCID-Profile: Ian F Tannock

Zitieren

APA

Tannock, I. F., Aggarwal, A., Verduzco-Aguirre, H., & Wilson, B. E. (2026). Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-517738

Vancouver

Tannock IF, Aggarwal A, Verduzco-Aguirre H, Wilson BE. Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-517738

BibTeX
@article{Tannock2026,
  author = {Tannock, Ian F and Aggarwal, Ajay and Verduzco-Aguirre, Haydee and Wilson, Brooke E},
  title = {Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1200/edbk-26-517738}
}
Kostenlos starten →